GSK chair buys 2,500 shares at £21.14

GSK plc reported an insider share purchase by its Non-Executive Chair, Sir Jonathan Symonds.

Rhea-AI Filing Summary

GSK plc reported an insider share purchase by its Non-Executive Chair, Sir Jonathan Symonds. He bought 2,500 ordinary shares of 31¼ pence each at a price of £21.1400 per share on 5 February 2026 on the London Stock Exchange. This Form 6-K records the required PDMR (person discharging managerial responsibilities) transaction notification for the company’s ordinary shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share transaction did GSK (GSK) disclose in this Form 6-K?

GSK disclosed that Non-Executive Chair Sir Jonathan Symonds purchased 2,500 ordinary shares. The shares, each with a nominal value of 31¼ pence, were acquired at £21.1400 per share and are listed as a single transaction on the London Stock Exchange.

Who is the GSK (GSK) insider involved in the February 2026 share purchase?

The insider is Sir Jonathan Symonds, GSK’s Non-Executive Chair. He is classified as a person discharging managerial responsibilities (PDMR), so his purchase of 2,500 ordinary shares must be formally reported to comply with market disclosure requirements.

At what price were the GSK (GSK) shares bought and on which market?

Sir Jonathan Symonds bought GSK ordinary shares at a price of £21.1400 per share. The 2,500-share transaction took place on the London Stock Exchange (XLON), which is identified as the venue in the company’s disclosure.

When did the reported GSK (GSK) insider transaction occur?

The insider transaction occurred on 5 February 2026. GSK’s report states that Sir Jonathan Symonds completed the single purchase of 2,500 ordinary shares on that date, and the company later furnished this information through a Form 6-K filing.

What type of financial instrument did GSK (GSK) report in this transaction?

GSK reported ordinary shares of 31¼ pence each as the financial instrument. These ordinary shares, identified by ISIN GB00BN7SWP63, represent the company’s standard equity and were the subject of Sir Jonathan Symonds’ 2,500-share purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 09:35 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

​

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sir Jonathan Symonds
b)	Position/status	Non-Executive Chair
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Purchase of 2,500 Ordinary Shares
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.1400	2,500
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-02-05
f)	Place of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: February 06, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc